Impact of Glucagon‐Like Peptide‐1 Receptor Agonists on Proteinuria in Kidney Transplant Recipients

GLP-1 RAs demonstrated clinically significant improvements in proteinuria as early as 1 month post-initiation in KTRs. Proteinuria significantly improved from severely increased to moderately increased at 6 months following GLP-1 RAs, with good tolerability. GLP-1 RAs may offer renal benefits in KTRs with T2DM without compromising allograft function. Future studies should include closer monitoring of KTRs on immunosuppression with high gastrointestinal adverse effect profiles, and larger studies are needed to assess the long-term impact of GLP-1 RAs in KTRs irrespective of T2DM.